Stifel Nicolaus Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR)
Equities researchers at Stifel Nicolaus started coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $55.00 price target on the stock. Stifel Nicolaus’ target price suggests a potential upside of 82.54% from the company’s current […]
Equities researchers at Stifel Nicolaus started coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $55.00 price target on the stock. Stifel Nicolaus’ target price suggests a potential upside of 82.54% from the company’s current […]
